266 related articles for article (PubMed ID: 26965928)
1. The potential of deferasirox as a novel therapeutic modality in gastric cancer.
Choi JH; Kim JS; Won YW; Uhm J; Park BB; Lee YY
World J Surg Oncol; 2016 Mar; 14():77. PubMed ID: 26965928
[TBL] [Abstract][Full Text] [Related]
2. The iron chelator, deferasirox, as a novel strategy for cancer treatment: oral activity against human lung tumor xenografts and molecular mechanism of action.
Lui GY; Obeidy P; Ford SJ; Tselepis C; Sharp DM; Jansson PJ; Kalinowski DS; Kovacevic Z; Lovejoy DB; Richardson DR
Mol Pharmacol; 2013 Jan; 83(1):179-90. PubMed ID: 23074173
[TBL] [Abstract][Full Text] [Related]
3. Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo.
Harima H; Kaino S; Takami T; Shinoda S; Matsumoto T; Fujisawa K; Yamamoto N; Yamasaki T; Sakaida I
BMC Cancer; 2016 Aug; 16(1):702. PubMed ID: 27582255
[TBL] [Abstract][Full Text] [Related]
4. Iron chelator-induced apoptosis via the ER stress pathway in gastric cancer cells.
Kim JL; Lee DH; Na YJ; Kim BR; Jeong YA; Lee SI; Kang S; Joung SY; Lee SY; Oh SC; Min BW
Tumour Biol; 2016 Jul; 37(7):9709-19. PubMed ID: 26803514
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
[TBL] [Abstract][Full Text] [Related]
6. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
7. CDK-associated Cullin 1 can promote cell proliferation and inhibit cisplatin-induced apoptosis in the AGS gastric cancer cell line.
Zheng Q; Zhao LY; Kong Y; Nan KJ; Yao Y; Liao ZJ
World J Surg Oncol; 2013 Jan; 11():5. PubMed ID: 23311997
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Salehi S; Saljooghi ASh; Shiri A
Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
[TBL] [Abstract][Full Text] [Related]
9. The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1.
Ohyashiki JH; Kobayashi C; Hamamura R; Okabe S; Tauchi T; Ohyashiki K
Cancer Sci; 2009 May; 100(5):970-7. PubMed ID: 19298223
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of the antitumoral activity of deferasirox, an iron chelation agent, on mantle cell lymphoma.
Vazana-Barad L; Granot G; Mor-Tzuntz R; Levi I; Dreyling M; Nathan I; Shpilberg O
Leuk Lymphoma; 2013 Apr; 54(4):851-9. PubMed ID: 23020673
[TBL] [Abstract][Full Text] [Related]
11. The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Kamihara Y; Takada K; Sato T; Kawano Y; Murase K; Arihara Y; Kikuchi S; Hayasaka N; Usami M; Iyama S; Miyanishi K; Sato Y; Kobune M; Kato J
Oncotarget; 2016 Sep; 7(39):64330-64341. PubMed ID: 27602957
[TBL] [Abstract][Full Text] [Related]
12. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
13. BI2536, a potent and selective inhibitor of polo-like kinase 1, in combination with cisplatin exerts synergistic effects on gastric cancer cells.
Lian G; Li L; Shi Y; Jing C; Liu J; Guo X; Zhang Q; Dai T; Ye F; Wang Y; Chen M
Int J Oncol; 2018 Mar; 52(3):804-814. PubMed ID: 29393385
[TBL] [Abstract][Full Text] [Related]
14. Interference of lysine-specific demethylase 1 inhibits cellular invasion and proliferation in vivo in gastric cancer MKN-28 cells.
Li Y; Tian X; Sui CG; Jiang YH; Liu YP; Meng FD
Biomed Pharmacother; 2016 Aug; 82():498-508. PubMed ID: 27470390
[TBL] [Abstract][Full Text] [Related]
15. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targeting caspase.
Kim JL; Kang HN; Kang MH; Yoo YA; Kim JS; Choi CW
Acta Haematol; 2011; 126(4):241-5. PubMed ID: 21951998
[No Abstract] [Full Text] [Related]
16. Arctigenin induces cell cycle arrest by blocking the phosphorylation of Rb via the modulation of cell cycle regulatory proteins in human gastric cancer cells.
Jeong JB; Hong SC; Jeong HJ; Koo JS
Int Immunopharmacol; 2011 Oct; 11(10):1573-7. PubMed ID: 21621647
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
[TBL] [Abstract][Full Text] [Related]
18. Effects of Iron Chelation in Osteosarcoma.
Argenziano M; Di Paola A; Tortora C; Di Pinto D; Pota E; Di Martino M; Perrotta S; Rossi F; Punzo F
Curr Cancer Drug Targets; 2021; 21(5):443-455. PubMed ID: 33380300
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin.
Kim SY; Kim HP; Kim YJ; Oh DY; Im SA; Lee D; Jong HS; Kim TY; Bang YJ
Int J Oncol; 2008 Jan; 32(1):89-95. PubMed ID: 18097546
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox has strong anti-leukemia activity but may antagonize theanti-leukemia effect of doxorubicin.
Chang YC; Lo WJ; Huang YT; Lin CL; Feng CC; Lin HT; Cheng HC; Yeh SP
Leuk Lymphoma; 2017 Sep; 58(9):1-12. PubMed ID: 28140713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]